Trial Profile
A Randomized Double-Blind Controlled Trial of Everolimus in Individuals With PTEN Mutations (RAD001XUS257T)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Multiple hamartoma syndrome
- Focus Adverse reactions
- Acronyms RAD001XUS257T
- 07 Feb 2022 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Sep 2021.
- 04 Aug 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2020.